首页> 外文会议>IEEE International Symposium on Computational Intelligence and Informatics >Identification of C38 colon adenocarcinoma growth under bevacizumab therapy and without therapy
【24h】

Identification of C38 colon adenocarcinoma growth under bevacizumab therapy and without therapy

机译:展鉴定Bevacizumab疗法下C38结肠腺癌生长,无需治疗

获取原文

摘要

Model identification allows to design different control strategies for antiangiogenic cancer therapy, and create model-based treatment protocols. These model-based protocols can be more effective than the current ones, since they provide individual treatment for the patients. The aim of this paper is to investigate C38 colon adenocarcinoma growth in three different cases: (1) tumor growth without therapy, (2) tumor growth with one Avastin dose for a 18-day therapy (10 mg/kg), (3) tumor growth with one-tenth dose of control Avastin dose spread over 18 days. Parametric model identification was carried out for these three cases and the relationship between the measured tumor attributes (volume, mass and vascularization) was analyzed. Effect of low-dose therapy was also examined.
机译:模型识别允许为抗血管生成癌症治疗设计不同的控制策略,并造成基于模型的治疗方案。 这些基于模型的协议可以比当前的那些更有效,因为它们为患者提供个体治疗。 本文的目的是探讨三种不同情况下的C38结肠腺癌生长:(1)肿瘤生长无需治疗,(2)肿瘤生长用一种Avastin剂量为18天治疗(10 mg / kg),(3) 肿瘤生长含有第十剂量的对照剂量剂量超过18天。 对这三种情况进行了参数模型鉴定,分析了测量的肿瘤属性(体积,质量和血管化)之间的关系。 还检查了低剂量治疗的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号